[go: up one dir, main page]

HK1243351A1 - 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物 - Google Patents

一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物 Download PDF

Info

Publication number
HK1243351A1
HK1243351A1 HK18102971.9A HK18102971A HK1243351A1 HK 1243351 A1 HK1243351 A1 HK 1243351A1 HK 18102971 A HK18102971 A HK 18102971A HK 1243351 A1 HK1243351 A1 HK 1243351A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
composition according
disintegrating agent
acceptable salt
dissolution
Prior art date
Application number
HK18102971.9A
Other languages
English (en)
Inventor
卢韵
盧韻
张新华
丁欢
張新華
张代美
丁歡
張代美
Original Assignee
江苏恒瑞医药股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 江苏恒瑞医药股份有限公司 filed Critical 江苏恒瑞医药股份有限公司
Publication of HK1243351A1 publication Critical patent/HK1243351A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
HK18102971.9A 2016-02-04 2017-01-23 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物 HK1243351A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610080476 2016-02-04
CN201610080476.X 2016-02-04
PCT/CN2017/072213 WO2017133542A1 (zh) 2016-02-04 2017-01-23 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物

Publications (1)

Publication Number Publication Date
HK1243351A1 true HK1243351A1 (zh) 2018-07-13

Family

ID=59500122

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18102971.9A HK1243351A1 (zh) 2016-02-04 2017-01-23 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物

Country Status (4)

Country Link
CN (1) CN107405350A (zh)
HK (1) HK1243351A1 (zh)
TW (1) TWI737673B (zh)
WO (1) WO2017133542A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020253808A1 (zh) * 2019-06-20 2020-12-24 江苏恒瑞医药股份有限公司 一种药物组合物以及其制备方法
WO2022042738A1 (zh) * 2020-08-31 2022-03-03 甘李药业股份有限公司 一种含cdk4/6抑制剂的药物组合物
TW202245782A (zh) * 2021-03-03 2022-12-01 大陸商蘇州盛迪亞生物醫藥有限公司 一種包含吡啶并嘧啶類衍生物的醫藥組成物及其製備方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3501696A1 (de) * 1985-01-19 1986-07-24 Bayer Ag, 5090 Leverkusen Pyridopyrimidine, mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
CN104470921B (zh) * 2013-05-17 2017-05-03 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
CN106795159B (zh) * 2015-04-22 2018-12-28 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法

Also Published As

Publication number Publication date
TWI737673B (zh) 2021-09-01
CN107405350A (zh) 2017-11-28
WO2017133542A1 (zh) 2017-08-10
TW201728329A (zh) 2017-08-16

Similar Documents

Publication Publication Date Title
EP3317281B1 (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
CN112402385A (zh) 4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法
US10160759B2 (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
CN107137408A (zh) 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
CN107137409A (zh) 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
HK1243351A1 (zh) 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物
HUE030982T2 (en) Pharmaceutical preparation
CN104098570A (zh) 替卡格雷晶型及其制备方法和用途
CN107028899B (zh) 一种含有吡啶并嘧啶类衍生物或其可药用盐的药物组合物
CN110650960B (zh) Acalabrutinib的新晶型及其制备方法和用途
EP3650025A1 (en) Pharmaceutical composition and method for preparing same
CN113521074B (zh) 一种包含喹啉类TGF-β1抑制剂的组合物及其用途
CN114306255A (zh) 一种甲基酮类衍生物药物制剂及其制备方法
CN101921227B (zh) 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
EP4631496A1 (en) Solid dispersion, preparation method therefor, and use thereof
JP7648238B2 (ja) トリアゾロピラジン誘導体化合物を有効成分とする薬学的組成物のタブレット錠の製造方法
CN112656796B (zh) 一种n-(5-甲基-1h-吡唑-3-基)吡啶-2-胺类药物的制剂组合物
CN112641782B (zh) 一种fgfr4抑制剂的制剂组合物、制备方法及其用途
CN113372345B (zh) 氘代杂环类激酶抑制剂
CN116891438A (zh) 含芳氨基喹唑啉的化合物的盐及其制备方法和用途
WO2023186031A1 (zh) 多靶点蛋白激酶抑制剂的药物组合物及其用途和制备方法
CN116836177A (zh) 一种蛋白激酶抑制剂的枸橼酸盐、其晶型、制备方法和用途
WO2024153053A1 (zh) Cdk抑制剂及其可药用盐的晶型以及其用途
KR20260004469A (ko) Fgfr4 억제제 조성물, 이의 제조 방법 및 약학적 응용
HK40099362A (zh) (s)-4-(8-氨基-3-(1-(丁‑2‑炔酰基)吡咯烷-2-基)咪唑并[1，5-a]吡嗪-1-基)-n-(吡啶-2-基)苯甲醯胺的固体形式和制剂